The first BRAF inhibitor, vemurafenib, was approved in the USA in 2011 following the results of a phase 3 trial (BRIM‐3) comparing it to dacarbazine in BRAF‐mutated melanoma.53 The gene discussed is BRAF; the disease is melanoma.